Standout Papers

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 D... 2013 2026 2017 2021 742
  1. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease (2013)
    Sunder Mudaliar, Robert R. Henry et al. Gastroenterology

Citation Impact

1 by Nobel laureates 11 from Science/Nature 108 standout
Sub-graph 1 of 17

Citing Papers

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024 Standout
New and emerging treatments for metabolic dysfunction-associated steatohepatitis
2024 Standout
5 intermediate papers

Works of Paul Dillon being referenced

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
2013 Standout
A NEW THERAPY FOR NONALCOHOLIC FATTY LIVER DISEASE AND DIABETES? INT-747-THE FIRST FXR HEPATIC THERAPEUTIC STUDY
2009

Author Peers

Author Epidemiology Toxicology Clinical Psychology Pharmacology Last Decade Papers Cites
Paul Dillon 1127 637 529 741 63 3.1k
Karen O. Allen 36 2 10 453
Edoardo Greppi 3 13
Jane Waters 45 18 356
J.H. Spijker 13 312
Paresh Wankhade 1 1 40 1 35 383

All Works

Loading papers...

Rankless by CCL
2026